GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Current Ratio

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Current Ratio : 0.06 (As of Aug. 2023)


View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. IntelliPharmaCeutics International's current ratio for the quarter that ended in Aug. 2023 was 0.06.

IntelliPharmaCeutics International has a current ratio of 0.06. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If IntelliPharmaCeutics International has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for IntelliPharmaCeutics International's Current Ratio or its related term are showing as below:

IPCIF' s Current Ratio Range Over the Past 10 Years
Min: 0.04   Med: 0.33   Max: 2.59
Current: 0.06

During the past 13 years, IntelliPharmaCeutics International's highest Current Ratio was 2.59. The lowest was 0.04. And the median was 0.33.

IPCIF's Current Ratio is ranked worse than
97.62% of 1555 companies
in the Biotechnology industry
Industry Median: 3.77 vs IPCIF: 0.06

IntelliPharmaCeutics International Current Ratio Historical Data

The historical data trend for IntelliPharmaCeutics International's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Current Ratio Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.64 0.20 0.15 0.11 0.04

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.04 0.06 0.07 0.06

Competitive Comparison of IntelliPharmaCeutics International's Current Ratio

For the Biotechnology subindustry, IntelliPharmaCeutics International's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Current Ratio distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Current Ratio falls into.



IntelliPharmaCeutics International Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

IntelliPharmaCeutics International's Current Ratio for the fiscal year that ended in Nov. 2022 is calculated as

Current Ratio (A: Nov. 2022 )=Total Current Assets (A: Nov. 2022 )/Total Current Liabilities (A: Nov. 2022 )
=0.493/12.009
=0.04

IntelliPharmaCeutics International's Current Ratio for the quarter that ended in Aug. 2023 is calculated as

Current Ratio (Q: Aug. 2023 )=Total Current Assets (Q: Aug. 2023 )/Total Current Liabilities (Q: Aug. 2023 )
=0.862/14.442
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IntelliPharmaCeutics International  (OTCPK:IPCIF) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


IntelliPharmaCeutics International Current Ratio Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.